Biotech company developing cystic fibrosis drugs signs partnerships with Edinburgh and Strathclyde academics

A pioneering Lanarkshire biotech company developing medicines to battle cystic fibrosis and heart disease has signed a partnership with Strathclyde and Edinburgh universities.

Lamellar Biomedical, based at Maxim 1, at Eurocentral and backed by Scottish Enterprise, Invesco, Barwell, TRI Capital, announced two research partnerships to optimise its Lamellasome nucleic acid technology and build its manufacturing capabilities.

Lamellar Biomedical, founded in 2007, is developing its own pipeline of therapeutics targeting the unmet clinical needs of idiopathic pulmonary fibrosis and cystic fibrosis. The company believes Lamellasome will play a key role in realising the potential of many of the nucleic acids in development, including siRNAs, microRNAs, mRNAs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.

Read more HERE.